Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02551237
Other study ID # PRODIGE 42 GERICO12/UCGI
Secondary ID 2015-A01365-44UC
Status Completed
Phase Phase 3
First received
Last updated
Start date January 7, 2016
Est. completion date June 2022

Study information

Verified date October 2023
Source UNICANCER
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the study is to compare pre-operative radio-chemotherapy (RT + capecitabine) to a short course RT associated with a delayed surgery, with two primary objectives: the efficacy evaluation (rate of R0 resection) and the preservation of autonomy (score IADL).


Description:

Colorectal cancer is one of the most frequent cancers diagnosed in France. The average age of diagnosis in 2012 was 70 years old for men and 73 years for women, confirming that colorectal cancer is a disease of the elderly population. The literature concerning combined treatments of colorectal cancer in the elderly is extremely limited. The application of combined treatments in the geriatric population is associated with an increase in the therapeutic complications. These post-operative complications together with the comorbidities and age are unfavorable prognostic factors for survival in patients with cancer of the rectum; this explains why the improved results obtained during the last decades are perceptible in younger patients and not in the elderly. In the general population, pre-operative radio-chemotherapy has imposed itself as a standard treatment for the cancer of the rectum locally advanced. The utilization of fluoropyrimidines associated with radiotherapy (RT) delivered in fractions [long course RT (50 Gy in 5 weeks), surgery planned 6 to 8 weeks later] increases the complete histological response rate and decreases significantly the rate of local relapse. The short-course RT [short course RT using the Swedish model (5x5 Gy in 5 days), with the surgery programmed the following week] is the standard neoadjuvant protocol in an important number of countries and/or academic groups. The studies that have compared the fractioned RT scheme to the short-course RT protocols have not shown any evidence of a change in efficacy of the short course RT concerning the following criteria: rate of R0 resection, rate of sphincter conservation, rate of relapse at 3 years, the disease free survival or the overall survival. Similarly, there appears to be no difference in severe toxicities in the long term. It should however be noted that short-course RT followed by immediate surgery may be less efficient than combined treatment in patients with a distal T3 cancer, even though these conclusions published by Ngan have been criticized by certain. On the other hand, the fractioned combined treatments results in more tumor and stage reduction and thus more sterilization. Nevertheless a retrospective analysis, performed in the Stockholm region, in patients irradiated with short-course protocol but operated with a delay of at least 4 weeks resulted in a sterilization rate of 8%. This result is even more interesting since in this cohort, 46% of the patients had a tumor classified T4 and that 38% of the patients had a primitive tumor considered inoperable. In the elderly population, the neoadjuvant treatment has rarely been studied. An exploratory analysis of the PRODIGE 2 study, based on age as the criteria, has shown that pre-operative radio-chemotherapy is significantly more toxic in the elderly population, from 70 years of age. Globally the lower tolerance for the pre-operative radio-chemotherapy results in more frequent early termination of RT and a statistically significant decrease in the number of patients operated. Furthermore, if the type of surgery was not significantly different between patients <70 years and those ≥70 years, we observe a non-significant increase in the rate of prolonged stoma (patients amputated without closure of the stoma). These differences in the surgical procedures is also observed in other publications, placing the emphasis on the fact that in the absence of any difference in the clinical presentation or the characteristic of the tumor, the risk of real or supposed decompensation modifies the surgical care. These data, as well as those in the literature, provides evidence that the pre-operative radio-chemotherapy strategy followed by surgery, the standard strategy in younger patients, is associated with more side effects in the elderly, resulting in the benefit-risk balance, in this population, to be more questionable. It is therefore necessary to conduct a specific studies in the elderly population, with cancer of the rectum with the objective to maintain the carcinological results obtained with classical radio-chemotherapy with at the same time better controlling the secondary effects of the treatment and the risk of decompensation of the patients: the short course radiotherapy associated with a delayed surgery may be a therapeutic scheme well adapted to this population. The investigators therefore propose a study comparing pre-operative radio-chemotherapy (RT + capecitabine) to a short course RT associated with a delayed surgery, with two primary objectives: the efficacy evaluation (rate of R0 resection) and the preservation of autonomy (score IADL).


Recruitment information / eligibility

Status Completed
Enrollment 103
Est. completion date June 2022
Est. primary completion date August 29, 2020
Accepts healthy volunteers No
Gender All
Age group 75 Years and older
Eligibility Inclusion Criteria: - Patient =75 years - Eastern Cooperative Oncology Group (ECOG) =2 - Adenocarcinoma of the rectum histologically proven - Tumor =12 cm from the anal margin, the measurement done by rigid rectoscopy or by sub peritoneal MRI - Require a pre-operative treatment (tumor classified T3 or T4 resectable by MRI and tomodensitometry or T2 of the very low rectum) - Patient operable - No radiologically detectable metastases - Absolute Neutrophile count (ANC) =1500/mm³; Platelets =100 000/mm³ and Hemoglobin =10 g/dL - Bilirubin =1.5 x upper limit of normal (ULN), aspartate aminotransferase (ASAT) and alanine aminotransferase (ALAT) =1.5 x upper limit of normal (ULN), Alkaline Phosphatase =1.5 x upper limit of normal (ULN) - Creatinine clearance =30 ml/min (Cockcroft and Gault) - Uracilemia < 16ng/mL - Public or private Health Insurance coverage - Patient has been informed and signed the informed consent document Exclusion Criteria: - Non-resectable tumor - History of chronic diarrhea or an inflammatory disease of the colon or rectum, or intestinal obstruction or sub-obstruction - History of pelvic radiotherapy - Any active febrile infection or any other serious underlying pathology that may prevent the patient from receiving the treatment - Significant Cardiovascular diseases such as, but not limited to: cardiovascular or myocardial infarction =6 months before inclusion, congestive heart failure class II or higher (NYHA), unstable angina, arrhythmia requiring medication or uncontrolled hypertension; - Significative cardiovascular conditions such as, but not limited to : Cardiac angioplasty or stenting, Myocardial infarction, Unstable angina, Coronary artery bypass graft surgery Symptomatic peripheral vascular disease, Class III or IV congestive heart failure, as defined by the New York Heart Association (NYHA), clinically significant irregular heartbeat requiring medication - Severe and unexpected reactions to fluoropyrimidine therapy - Any contra-indication to capecitabine and its excipients; patients with hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not included. - Uracilemia = 16ng/mL - Any other concomitant cancer or history of cancer in the last 3 years, with the exception of the in situ cancer of the uterus, treated, or squamous-cell or basal-cell carcinoma. - Patients already included in another therapeutic trail with an experimental molecule - Person deprived of liberty - Patient that for geographical, social and/or physical reasons will not be able to follow the procedure as required by the protocol

Study Design


Related Conditions & MeSH terms


Intervention

Radiation:
50 Gy
radiotherapy 50 Gy in 25 fractions of 2 Gy, five times per week, over a period of 5 weeks
Drug:
Capecitabine
oral capecitabine 800 mg/m2 twice daily from the first day of radiotherapy and given 5 days per week during radiotherapy.
Radiation:
25 Gy
radiotherapy 25 Gy in 5 fractions of 5 Gy delivered in one week (short-course arm)

Locations

Country Name City State
France Centre Hospitalier d'Abbeville Abbeville
France Clinique Claude Bernard Albi
France CHU Amiens Picardie Amiens
France Polyclinique Maymard Bastia
France Centre Hospitalier de Beauvais Beauvais
France CHU de Besançon Besancon
France Cebtre Hospitalier de Blois Blois
France Hôpital Avicenne Bobigny
France Institut Bergonié Bordeaux
France Centre François Baclesse Caen
France CHU Henri Mondor Créteil
France Centre Hospitalier de Dax Dax
France Centre Georges François Leclerc Dijon
France CHU DIJON (Hôpital du Bocage) Dijon
France CHIC des Alpes du Sud- site de Gap GAP
France CHU de Grenoble Hôpital A Michallon Grenoble
France Hôpital Privé Sainte Marguerite Hyeres
France CHD de Vendée La Roche-sur-yon
France Institut Hospitalier Franco-Britannique Levallois-perret
France Centre Hospitalier Universitaire de Limoges Limoges
France Centre Léon Bérard Lyon
France Hôpital privé Jean Mermoz Lyon
France CHU Timone Marseille
France Institut Paoli Calmettes Marseille
France Centre azuréen de cancérologie Mougins
France Hôpital Américain de Paris Neuilly-sur-seine
France Centre Antoine Lacassagne Nice
France Chu Caremeau Nimes
France Centre Médical Oncogard Institut de cancérologie du Gard Nîmes
France Hôpital TENON Paris
France CHU de Bordeaux Pessac
France Centre Hospitalier Annecy Genevois Pringy
France Centre Henri Becquerel Rouen
France Hôpital d'instruction des Armées Saint Mande
France Clinique Pasteur Toulouse
France Institut de Cancérologie de Lorraine Vandoeuvre Les Nancy
France Gustave Roussy Cancer Campus Grand Paris Villejuif

Sponsors (1)

Lead Sponsor Collaborator
UNICANCER

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary R0 resection rate Compare the efficacy between the arm A and the arm B (with an objective of non-inferiority) 3 months
Primary IADL (Instrumental Activities of Daily Living) Score Compare the maintenance of autonomy between the arm A and arm B (with an objective of superiority) 1 year
Secondary Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.03 Description of the Adverse Events during the pre-operative period. 3 months
Secondary Post-operative complications according to Dindo-Clavien classification 3 months
Secondary Death rate Death rate is defined as the percentage of patients who died since the date of randomisation at 6 and 12 months post-surgery (M6 and M12) from any cause at 6 and 12 months
Secondary Overall survival (OS) The OS is defined as the interval between the date of randomization and the date of deaths from any cause 10 years
Secondary Specific survival The specific survival is defined as the interval between the date of randomization and the date of deaths due to cancer. 10 years
Secondary Disease free survival The disease free survival is defined as the interval between the date of randomization and the date of cancer relapse (local regional or distant), second cancer or death from any cause. 10 years
Secondary Loco-regional disease free survival The disease free survival is defined as the interval between the date of randomization and the date of cancer relapse (local or regional). 10 years
Secondary Rate of stoma percentage of patients with definitive or transitional stoma after surgery. at 6 and 12 months
Secondary Instrumental Activities of Daily Living (IADL) Autonomy Assessment Baseline, within 2 weeks before surgery and 3, 6 and 12 months after surgery
Secondary Activities of Daily Living (ADL) Autonomy Assessment Baseline, within 2 weeks before surgery and 3, 6 and 12 months after surgery
Secondary Questionnaire G8 Geriatric Screening Baseline, within 2 weeks before surgery and 3, 6 and 12 months after surgery
Secondary Mini-Mental Score Examination (MMSE) Cognitive functioning Baseline, within 2 weeks before surgery and 3, 6 and 12 months after surgery
Secondary Walking gate Baseline, within 2 weeks before surgery and 3, 6 and 12 months after surgery
Secondary Geriatric Depression Scale (GDS15) Depression Assessment Baseline, within 2 weeks before surgery and 3, 6 and 12 months after surgery
Secondary Charlson score Comorbidities evaluation Baseline, within 2 weeks before surgery and 3, 6 and 12 months after surgery
Secondary Mini Nutritional Assessment (MNA) Nutritional Evaluation Baseline, within 2 weeks before surgery and 3, 6 and 12 months after surgery
Secondary EORTC QLQ-C30 + EDL14 Quality of Life (QLQ) Baseline, within 2 weeks before surgery and 3, 6 and 12 months after surgery
See also
  Status Clinical Trial Phase
Active, not recruiting NCT01227239 - Preoperative S-1/OHP With Radiation Therapy for Low-lying Rectal Carcinoma in Neo-adjuvant Setting Phase 1/Phase 2
Recruiting NCT01459328 - Resource-Sparing Curative Treatment for Rectal Cancer Phase 3
Recruiting NCT04078828 - PR in Endoscopic LAR for Rectal Cancer N/A
Not yet recruiting NCT06424522 - A Bowel Management Program (Retrograde Rectal Enema) for the Treatment of Low Anterior Resection Syndrome in Rectal Cancer Patients Early Phase 1
Terminated NCT02797405 - Tumour and HEalthy Tissues DOse-response and Radiosensitivity Assay N/A
Completed NCT01751516 - PET/MRI as a Predictor of Response to Pre-op Chemoradiation in Resectable Rectal Cancer: a Pilot Study
Terminated NCT01111292 - Inositol in Preventing Colorectal Cancer in Patients With Colitis-Associated Dysplasia Phase 1/Phase 2
Completed NCT00682786 - Genotype-directed Neoadjuvant Chemoradiation for Rectal Carcinoma Phase 2
Completed NCT02000050 - Phase II Study of Up-front Chemotherapy and Neo-adjuvant Short-course Radiotherapy for Resectable Rectal Carcinoma (COLORE) Phase 2
Recruiting NCT04749108 - Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma Phase 2/Phase 3
Active, not recruiting NCT01696981 - Screening for Colorectal Cancer in Older Patients (PLCO Screening Trial) N/A
Active, not recruiting NCT01899547 - Laparoscopy-Assisted Surgery for Carcinoma of the Low Rectum N/A
Completed NCT01333709 - Multicenter Phase 2 Trial: a Tailored Strategy for Locally Advanced Rectal Carcinoma Phase 2
Recruiting NCT04848311 - Indocanine Green as Tracer for Lymph Nodes Dissection in Station 253 N/A
Not yet recruiting NCT02770911 - Laparoscopic Anterior Resection With or Without "Dog Ear" Double-stapled Anastomosis for Rectal Cancer Phase 3
Active, not recruiting NCT02432963 - Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy Phase 1
Active, not recruiting NCT04505553 - Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer Phase 2
Completed NCT01372007 - Influence of Somatuline Autogel 120mg on Post-operative Drainage After Total Mesorectum Excision for Rectumcarcinoma Phase 3
Active, not recruiting NCT02817126 - Robot-assisted Versus Laparoscopic Surgery for Mid/Low Rectal Cancer N/A
Active, not recruiting NCT04713618 - Changes in Pelvic Health, Sexual Function, and Quality of Life in Women With Pelvic Cancer Undergoing Radiation Therapy